Organic cation/carnitine transporters (OCT/N) mediate uptake of positively charged molecules. Their role in lung epithelium, however, is not well understood. OCT/N expression and activity was studied in cell lines of human alveolar (A549), bronchial (16HBE14o-and Calu-3) and intestinal (Caco-2) epithelium. Protein levels were largely comparable for all OCT/Ns in the respiratory epithelial cell lines studied, however, OCT2 was exclusively observed in A549 cells. OCT1 and -2 were present at significantly higher levels in Caco-2 cells, compared with the pulmonary epithelial cell types. OCTN1 and -2 were also more abundant in Caco-2. Only OCT3 was expressed evenly across all cell lines investigated. .5 μM, respectively. This uptake was sensitive to organic cations, but insensitive to carnitine and lysine. We conclude that uptake of organic cations is facilitated by distinct pathways in different regions of lung mucosa. Luminally localised OCT2 appears to be exclusively involved in the alveolar epithelium, whereas basolateral localised OCT3 might play a role in alveolar as well as in bronchial epithelial cells.
INTRODUCTION
Although the body of literature on disposition of inhaled medicines is increasing, there is still a surprising lack of mechanistic information on the processes involved (1) . To further complicate matters, a broad range of different epithelial cell types, which change significantly in phenotype depending on their localisation, is found along the mucosal surface of the lung (2) . It is now widely accepted that membrane transporters impact on the absorption and extrusion of drugs resulting in alterations of their pharmacokinetics and pharmacodynamics, potentially leading to organ toxicity. The study of drug transporters, however, has been mainly focused on the liver, kidneys, gut and also the blood-brain barrier, with the lung remaining largely unchartered terrain (3, 4) .
The largest group of transporters are the SoLute Carrier (SLC) proteins with approximately 320 genes in 43 families (5) . SLC transporters are often found in epithelial membranes and mediate uptake and secretion of (among many other substrates) organic cations (6) .
Numerous drug molecules, because of their structural similarity to endogenous compounds, are also substrates of SLC transporters. Transporters involved in organic cation translocation are electrogenic cation transporters OCT1-3 (SLC22A1-3), cation and carnitine transporters OCTN1 and OCTN2 (SLC22A4-5), proton/cation antiporters of the MATE family (SLC47A1-2), monoamine neurotransmitter transporters (SLC6 family), cationic amino acid transporters (SLC7 family), nucleoside transporters (SLC28A1-3 and SLC29A1-4) and several choline transporters (SLC5A7 and SLC44A1-4) (7, 8) .
Evidence is now emerging that organic cation transporters are involved in transport processes in various cell types of the lung (9, 10) . Epithelial surface cells (11) , but also airway smooth muscle cells (12) have been suggested to functionally express members of the SLC22A family of proteins. Hence, it was one of the aims of this work to investigate the expression levels of the five human OCT/N members in alveolar epithelial A549 and the bronchial epithelial 16HBE14o-and Calu-3 cell lines; all well established in vitro models used in biopharmaceutical sciences (13, 14) .
The second aim of this paper was to use 4-[4-(dimethylamino)styryl]-N-methylpyridinium iodide (ASP + ) as a non-radioactive OCT/N probe (15, 16) , and to study the mechanisms of organic cation transport across distinct lung epithelia, with particular emphasis on OCT/Nmediated drug-drug interactions. Commonly prescribed inhalation medicines such as β 2 -agonists and anti-cholinergic drugs carry a cationic charge at physiological pH, but have to cross the epithelial barrier in order to reach the β 2 -adrenoceptor localised to the airway smooth muscles. Data from our laboratory and others suggest that β 2 -agonists are transported by OCT/N, or at least interfere with OCT/N function (17, 18) . The well characterised human intestinal epithelial cell line, Caco-2, was also included in our study, in order to investigate if any differences in transporter expression and function exist between the epithelia of the gut and the lung.
MATERIAL AND METHODS

2.1
Chemicals. Uptake inhibition experiments were carried out in the presence of amantadine (100 μM and 500 μM), D-carnitine (10 μM and 100 μM), L-carnitine (100 μM and 500 μM), verapamil ( To indirectly investigate the localisation of transporters involved in ASP + uptake, studies in Calu-3 monolayers were carried out in the presence of 5 mM EDTA in KRB for 15 min.
EDTA will form complexes with multivalent cations, such as, calcium ions and thus lead to an opening of the tight junctional complexes, allowing ASP + access to transporter sites localised to the basolateral membranes.
The fluorescence activity of samples was analysed in 24-well plates using an automated plate reader (FLUOstar Optima, BMG Labtech, Offenburg, Germany) at excitation and emission wavelengths of 485 and 590 nm, respectively. Samples were diluted with KRB, where appropriate. Total cell protein was determined by bicinchoninic acid (BCA) assay according to the manufacturer's instructions (Pierce, Thermo Scientific, Rockford, USA).
Kinetic analysis.
Half-saturation constant (K m ) and maximum uptake or release rates 
2.6
Statistical analysis. All experiments were carried out at least in triplicate using cells from at least three different passages (n = 3-9). Results, expressed as mean ± S.D., were compared using one-way analysis of variance (ANOVA), followed by the Student-NewmanKeuls post hoc test. P < 0.05 was considered as significant. ASP + translocation across cellular membranes at 4°C was significantly reduced, when compared to data obtained at 37°C (data not shown).
3.3
Kinetics of ASP + uptake. In Figure 4 the concentration dependence of ASP + uptake into cell monolayers is depicted. ASP + uptake was observed to be a saturable process only in A549 cells ( Figure 4A ). An Eadie-Hofstee transformation, corrected for the non-saturable component of ASP + uptake into A549 cells, identified two distinct transporter sites ( Figure   4C ). The calculated kinetic parameters, K m and V max , are shown in Table 1 . Of note, substrate saturation was not reached for ASP + uptake into 16HBE14o-, Calu-3 and Caco-2 cell layers ( Figure 4B ).
3.4
Effect of extracellular conditions on ASP + uptake. To further characterise the mechanisms involved in organic cation transport at the respiratory epithelium, the effects of extracellular pH and membrane depolarisation on ASP + uptake were studied. The uptake of ASP + was significantly (P < 0.05) decreased in acidic conditions in all cell lines ( Figure 5A ).
There was, however, no further uptake observed at pH 8.2. In fact, uptake at high pH was reduced when compared to control values, i.e., pH 7.4 ( Figure 5A ). Membrane depolarisation, achieved by replacement of extracellular Na + with equimolar K + , also resulted in a significantly (P < 0.05) reduced ASP + uptake into human respiratory epithelial cells. This effect was most pronounced in the case of A549 cell monolayers ( Figure 5B ).
3.5
Effect of organic cations on ASP + uptake. The structural analogue, MPP + reduced ASP + uptake into A549 monolayers almost completely at 1 mM ( Figure 6A ). TEA, resulted in a concentration-dependent decrease of ASP + uptake and also verapamil significantly diminished ASP + uptake to <10% of control (at 200 μM). Both substances have the potential to inhibit OCT1-3 and OCTN1 and -N2 at the concentration range used (19) . The steroids, corticosterone, beclometasone and budesonide showed unequal effects. Corticosterone, which is known to inhibit OCT1, -2 and -3 reduced ASP + uptake by almost 80%, whilst both inhaled corticosteroids (ICS) caused a much lower, albeit significant, reduction. Amantadine, like the ICS, an inhibitor of mainly OCT2, had a more pronounced effect, but the concentrations used were also higher. . The OCTN substrates, ergothioneine and D-and L-carnitine reduced ASP + uptake to 70-80%. ASP + uptake was also inhibited by ~35%, when the choline transporter substrate HC-3 or acetylcholine was present in the transport buffer. L-lysine at 1 mM had no effect on ASP + accumulation.
A concentration-dependent attenuation of ASP + uptake into A549 cells was achieved with a rank order salmeterol (>90% at 100 μM) > formoterol (>80% at 500 μM) > salbutamol (>40% 500 μM) ( Figure 6A ). R-salbutamol proved to be a slightly, but not significantly more potent inhibitor of ASP + uptake than S-salbutamol (P = 0.06), whilst in the case of the formoterol, the SS-enantiomer was significantly (P < 0.05) more effective than the RRenantiomer. Cromolyn sodium did not show a concentration dependency, but both tested concentrations (100 μM and 500 μM) were able to reduce ASP + uptake by >20%.
A more limited set of compounds was tested in 16HBE14o-( Figure 6B ), Calu-3 ( Figure 6C) and Caco-2 (Figures 6D) cell monolayers. Whilst some inhibition of ASP + uptake was observed, the effects were generally much less pronounced when compared to A549 monolayers. In all three cell types amantadine significantly (P < 0.05) inhibited ASP + uptake at the higher concentration (i.e., 500 μM). A similar, but more pronounced effect was also Therefore, the enantiomers of salbutamol and formoterol were only tested in 16HBE14o-cells. In all cases a concentration dependent inhibition of ASP + uptake was observed. No distinction, however, could be made between the relevant enantiomers.
3.6
Contribution of tight junctions to ASP + uptake. Uptake of ASP + into Calu-3 monolayers was studied after the tight junctional complex was opened using EDTA complexation of calcium ions. When transporter sites localised to the basolateral membranes were accessible to ASP + , uptake was significantly increased (Figure 7 ).
4.
DISCUSSION
This work demonstrated the presence of specific transporters for the uptake of organic cations in continuously growing cell lines of respiratory epithelium. Moreover, it confirmed organic cation/carnitine transporter abundance in intestinal Caco-2 cell monolayers. Of note, previous literature on OCT/N expression in these in vitro models of pulmonary origin was almost entirely limited to genomic studies (9, (20) (21) (22) (23) . For example, in a gene expression study of human whole lung tissue based on a reference set of 19,000 genes, OCTN1 and OCTN2 appeared to be strongly expressed transcripts at the 50-75% quartile of gene expression intensity, whereas OCT1 and OCT3 were in the 25-50% quartile and OCT2 even lower at 0-25% (10).
Transporter expression. We confirmed by immunoblot that all five known isoforms of the human SLC22 organic cation/carnitine transporter family, i.e., OCT1, -2, -3 and OCTN1 and -N2 were present in the alveolar epithelial cell line, A549 as well as in intestinal epithelial
Caco-2 cells. This is consistent with previous observations of OCT1 (23) Quantitatively, OCT1 and OCT2 were detected at significantly higher levels in Caco-2 cells compared to the respiratory cell types. Only OCT3 was expressed at equivalent levels in all cell lines studied. Abundance of OCTN1 and OCTN2 was lower in the lung derived cells, but these differences were not as pronounced as in the case of OCT1 and -2.
Dependence of ASP + uptake on extracellular conditions. ASP + has been used as a nonradioactive substrate for monoamine and organic cation/carnitine transporters (15, 16, 18, (27) (28) (29) (30) . In our hands, ASP + uptake was concentration and temperature-dependent and sensitive to extracellular pH and membrane potential in all cell lines studied.
Horvath et al. (18) previously reported that ASP + uptake into human airway epithelial cells in primary culture on collagen-coated coverslips had a pH-profile, but was independent of extracellular Na + concentration. ASP + uptake into placental BeWo cells was mediated by a low-affinity, carrier-associated process exhibiting a K m of 580±110 μM, and asymmetric transport was observed, with greater permeability in the apical to basolateral direction (16) .
Whilst the authors of that study did not test for the presence of OCT3, OCTN1/2 or indeed any of the monoamine transporters, they concluded that ASP + uptake in their hands was not facilitated by OCT1 or OCT2. Bleasby and co-workers (10) No information on the cellular localisation of any of the OCT in A549, Calu-3 and 16HBE14o-cells is currently available. We have evaluated several commercially available antibodies and in our hands it was difficult to obtain reproducible results in confocal laser scanning microscopical analysis (data not shown). From the immunohistochemistry data of Lips and colleagues, however, it can be speculated that OCT2, if present, is localised to the apical membrane, whilst OCT3 is found in the basolateral membranes (11).
Our results showed that in alveolar A549 cells significantly higher OCT-mediated ASP + uptake occurred than in the other cell types. Sensitivity of this uptake to MPP + , TEA, verapamil, corticosterone, amantadine and the ICS compounds indicated an involvement of OCT2 and probably OCT3 (19, 34) . Interestingly, uptake rates in Calu-3 monolayers reached almost comparable levels, after opening the tight junctions with EDTA (35) . This strongly supports the notion that at least one of the responsible transporter sites is localised at the basolateral cell aspect. Under normal conditions, ASP + diffusion to the basolateral membrane will be restricted by the tight and adherens junctions, hence, it is unlikely that sufficiently high concentrations are achieved to saturate the transporter site. This is consistent with our observation that no saturation of ASP + absorption was observed in polarised Calu-3, 16HBE14o-and Caco-2 monolayers. The observation that cellular junctions in A549 cells are compromised, resulting in an inability of this cell line to form electrically tight monolayers when cultured on semi-permeable membranes, offers further support to this hypothesis (13) .
Most pharmacological inhibitors showed only relatively weak activities in 16HBE14o-, Calu-3 and Caco-2 monolayers. The exception to this was the highly lipophilic compound, verapamil. It is therefore possible that passive diffusion of verapamil into the cells occurred, resulting in the inhibition of these basolaterally localised transporters. The exact nature of the transporters involved, however, remains to be elucidated. OCT1 was found in all cell lines studied, but with pronounced differences in protein abundance. In addition, several studies have described the protein predominantly localised to intracellular domains in both Caco-2 cells as well as human bronchial epithelium (11, 24) . OCT3, on the other hand, was equivalently expressed across all cell types and has previously been associated with basolateral expression (11, 24) . It might hence be argued that OCT3 is the low affinity, high throughput transporter for ASP + in our study.
Cis-inhibition by ergothioneine and D-and L-carnitine only weakly attenuated ASP + uptake, suggesting that organic carnitine transporters had only a minor involvement in the process.
Horvath and colleagues (18) previously proposed OCTN2 as the responsible transporter for ASP + uptake into the human airway epithelium. Regretfully, their report fails to demonstrate direct evidence of ASP + transport by OCTNs. In addition, a recent publication by Grigat and co-workers (36) comes to the conclusion that OCTN2 is not a general drug transporter and hence, does not translocate ASP + in HEK-293 cells. Moreover, the data on the structural ASP + analogue, MPP + reports only a very weak affinity to OCTN transporters (19) . We therefore believe that OCTNs are not involved in ASP + uptake by the cell lines investigated in our work. ± SD, n = 3 -9.* P < 0.05, ** P < 0.01 versus control. Different absorption pathways for ASP + in alveolar, bronchial and intestinal epithelial cells.
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